drugset / Trial / NCT04418466
Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an Open-Label Study in Stable Schizophrenia Patients to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Risperidone to Risperidone Implant (DLP-114).
Timeline
- Start
- 2021-04-01
- Primary completion
- 2023-02-10
- Completion
- 2023-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risperidone | Other / unclassified | 360 mg | — |
| Subject | Risperidone | Other / unclassified | 435 mg | — |